Zhenwei Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhenwei Mao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jie Ma
School of Electrical and Information Engineering, Jiangsu University, Zhenjiang 212013, China
11 shared publications - Jie Tian
Department of Immunology, Jiangsu University School of Medicine, Zhenjiang, China
11 shared publications - Kai Yin
Department of General Surgery, Affiliated Hospital of Jiangsu University, Institute of Digestive Diseases, Jiangsu University, Zhenjiang, China
11 shared publications - Shengjun Wang
Department of Laboratory Medicine, Jiangsu Province Engineering Research Center for Precise Diagnosis and Treatment of Inflammatory Diseases, The Affiliated Hospital of Jiangsu University, Zhenjiang, China
11 shared publications - Wenxin Wang
Department of Immunology, Jiangsu University School of Medicine, Zhenjiang, China
11 shared publications - Xueli Xia
Department of General Surgery, Affiliated Hospital of Jiangsu University, Institute of Digestive Diseases, Jiangsu University. Zhenjiang, China
11 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Netrin-1 promotes the immunosuppressive activity of MDSCs in colorectal cancer
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Netrin-1 promotes the immunosuppressive activity of MDSCs in colorectal cancer
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Netrin-1 promotes the immunosuppressive activity of MDSCs in colorectal cancer
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Netrin-1 promotes the immunosuppressive activity of MDSCs in colorectal cancer
- Open Access
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Data from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
Myeloid-derived suppressive cells (MDSC) inhibit antitumor immunity and confer a survival advantage for tumor evasion. Tumor cells also support MDSC expansion and recruitment by secreting multiple growth factors and cytokines, but the mechanisms by which tumors affect MDSC function are not completely understood. Here, we found that the neuronal guidance protein netrin-1 was selectively secreted by MC38 murine colon cancer cells, which could enhance the immunosuppressive activity of MDSCs. MDSCs predominantly expressed one type of netrin-1 receptor, adenosine receptor 2B (A2BR). Netrin-1 interacted with A2BR on MDSCs to activate the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway, which ultimately increased CREB phosphorylation in MDSCs. Furthermore, netrin-1 knockdown in tumor cells inhibited the immunosuppressive activity of MDSCs and restored antitumor immunity in MC38 tumor xenograft mice. Intriguingly, high netrin-1 in the plasma correlated with MDSCs in patients with colorectal cancer. In conclusion, netrin-1 significantly enhanced the immunosuppressive function of MDSCs through A2BR on MDSCs, thus promoting the development of tumors. These findings highlight that netrin-1 may regulate the abnormal immune response in colorectal cancer and may become a potential target for immunotherapy.
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
Myeloid-derived suppressive cells (MDSC) inhibit antitumor immunity and confer a survival advantage for tumor evasion. Tumor cells also support MDSC expansion and recruitment by secreting multiple growth factors and cytokines, but the mechanisms by which tumors affect MDSC function are not completely understood. Here, we found that the neuronal guidance protein netrin-1 was selectively secreted by MC38 murine colon cancer cells, which could enhance the immunosuppressive activity of MDSCs. MDSCs predominantly expressed one type of netrin-1 receptor, adenosine receptor 2B (A2BR). Netrin-1 interacted with A2BR on MDSCs to activate the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway, which ultimately increased CREB phosphorylation in MDSCs. Furthermore, netrin-1 knockdown in tumor cells inhibited the immunosuppressive activity of MDSCs and restored antitumor immunity in MC38 tumor xenograft mice. Intriguingly, high netrin-1 in the plasma correlated with MDSCs in patients with colorectal cancer. In conclusion, netrin-1 significantly enhanced the immunosuppressive function of MDSCs through A2BR on MDSCs, thus promoting the development of tumors. These findings highlight that netrin-1 may regulate the abnormal immune response in colorectal cancer and may become a potential target for immunotherapy.
- Open Access
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Data from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
Myeloid-derived suppressive cells (MDSC) inhibit antitumor immunity and confer a survival advantage for tumor evasion. Tumor cells also support MDSC expansion and recruitment by secreting multiple growth factors and cytokines, but the mechanisms by which tumors affect MDSC function are not completely understood. Here, we found that the neuronal guidance protein netrin-1 was selectively secreted by MC38 murine colon cancer cells, which could enhance the immunosuppressive activity of MDSCs. MDSCs predominantly expressed one type of netrin-1 receptor, adenosine receptor 2B (A2BR). Netrin-1 interacted with A2BR on MDSCs to activate the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway, which ultimately increased CREB phosphorylation in MDSCs. Furthermore, netrin-1 knockdown in tumor cells inhibited the immunosuppressive activity of MDSCs and restored antitumor immunity in MC38 tumor xenograft mice. Intriguingly, high netrin-1 in the plasma correlated with MDSCs in patients with colorectal cancer. In conclusion, netrin-1 significantly enhanced the immunosuppressive function of MDSCs through A2BR on MDSCs, thus promoting the development of tumors. These findings highlight that netrin-1 may regulate the abnormal immune response in colorectal cancer and may become a potential target for immunotherapy.
- 3 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
Myeloid-derived suppressive cells (MDSC) inhibit antitumor immunity and confer a survival advantage for tumor evasion. Tumor cells also support MDSC expansion and recruitment by secreting multiple growth factors and cytokines, but the mechanisms by which tumors affect MDSC function are not completely understood. Here, we found that the neuronal guidance protein netrin-1 was selectively secreted by MC38 murine colon cancer cells, which could enhance the immunosuppressive activity of MDSCs. MDSCs predominantly expressed one type of netrin-1 receptor, adenosine receptor 2B (A2BR). Netrin-1 interacted with A2BR on MDSCs to activate the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway, which ultimately increased CREB phosphorylation in MDSCs. Furthermore, netrin-1 knockdown in tumor cells inhibited the immunosuppressive activity of MDSCs and restored antitumor immunity in MC38 tumor xenograft mice. Intriguingly, high netrin-1 in the plasma correlated with MDSCs in patients with colorectal cancer. In conclusion, netrin-1 significantly enhanced the immunosuppressive function of MDSCs through A2BR on MDSCs, thus promoting the development of tumors. These findings highlight that netrin-1 may regulate the abnormal immune response in colorectal cancer and may become a potential target for immunotherapy.
- Open Access
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
Myeloid-derived suppressive cells (MDSC) inhibit antitumor immunity and confer a survival advantage for tumor evasion. Tumor cells also support MDSC expansion and recruitment by secreting multiple growth factors and cytokines, but the mechanisms by which tumors affect MDSC function are not completely understood. Here, we found that the neuronal guidance protein netrin-1 was selectively secreted by MC38 murine colon cancer cells, which could enhance the immunosuppressive activity of MDSCs. MDSCs predominantly expressed one type of netrin-1 receptor, adenosine receptor 2B (A2BR). Netrin-1 interacted with A2BR on MDSCs to activate the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway, which ultimately increased CREB phosphorylation in MDSCs. Furthermore, netrin-1 knockdown in tumor cells inhibited the immunosuppressive activity of MDSCs and restored antitumor immunity in MC38 tumor xenograft mice. Intriguingly, high netrin-1 in the plasma correlated with MDSCs in patients with colorectal cancer. In conclusion, netrin-1 significantly enhanced the immunosuppressive function of MDSCs through A2BR on MDSCs, thus promoting the development of tumors. These findings highlight that netrin-1 may regulate the abnormal immune response in colorectal cancer and may become a potential target for immunotherapy.
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
Myeloid-derived suppressive cells (MDSC) inhibit antitumor immunity and confer a survival advantage for tumor evasion. Tumor cells also support MDSC expansion and recruitment by secreting multiple growth factors and cytokines, but the mechanisms by which tumors affect MDSC function are not completely understood. Here, we found that the neuronal guidance protein netrin-1 was selectively secreted by MC38 murine colon cancer cells, which could enhance the immunosuppressive activity of MDSCs. MDSCs predominantly expressed one type of netrin-1 receptor, adenosine receptor 2B (A2BR). Netrin-1 interacted with A2BR on MDSCs to activate the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway, which ultimately increased CREB phosphorylation in MDSCs. Furthermore, netrin-1 knockdown in tumor cells inhibited the immunosuppressive activity of MDSCs and restored antitumor immunity in MC38 tumor xenograft mice. Intriguingly, high netrin-1 in the plasma correlated with MDSCs in patients with colorectal cancer. In conclusion, netrin-1 significantly enhanced the immunosuppressive function of MDSCs through A2BR on MDSCs, thus promoting the development of tumors. These findings highlight that netrin-1 may regulate the abnormal immune response in colorectal cancer and may become a potential target for immunotherapy.
- Open Access
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
- Open Access
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer
- 12 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer